Published on 30 Jun 2021 on Insider Monkey via Yahoo Finance

Is Agile Therapeutics Inc (AGRX) A Good Stock To Buy?

As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the fourth quarter of 2019. A significant number of hedge funds continued their strong performance in 2020 and 2021 as well. We get to see hedge funds' thoughts towards the market and individual stocks by aggregating their quarterly portfolio movements and reading their investor letters. In this article, we will particularly take a look at what hedge funds think about Agile Therapeutics Inc (NASDAQ:AGRX).

Is AGRX a good stock to buy? Agile Therapeutics Inc (NASDAQ:AGRX) shareholders have witnessed a decrease in activity from the world's largest hedge funds in recent months. Agile Therapeutics Inc (NASDAQ:AGRX) was in 6 hedge funds' portfolios at the end of the first quarter of 2021. The all time high for this statistic is 15. Our calculations also showed that AGRX isn't among the 30 most popular stocks among hedge funds (click for Q1 rankings).

In the financial world there are a large number of tools investors have at their disposal to grade stocks. A pair of the most under-the-radar tools are hedge fund and insider trading indicators. We have shown that, historically, those who follow the top picks of the best fund managers can outperform the broader indices by a solid amount. Insider Monkey's monthly stock picks returned 206.8% since March 2017 and outperformed the S&P 500 ETFs by more than 115 percentage points (see the details here). That's why we believe hedge fund sentiment is a useful indicator that investors should pay attention to.